UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

Leukemia, 2019-10, Vol.33 (10), p.2442-2453

2019

Volltextzugriff (PDF)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker

Frontiers in oncology, 2019-01, Vol.8, p.645-645

2019

Volltextzugriff (PDF)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

Cell death & disease, 2020-05, Vol.11 (5), p.316-316, Article 316

2020

Volltextzugriff (PDF)

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition

Haematologica (Roma), 2022-12, Vol.107 (12), p.2905

2022

Volltextzugriff (PDF)

Osteoclasts support the survival of human plasma cells in vitro

International immunology, 2008-06, Vol.20 (6), p.775-782

2008

Volltextzugriff (PDF)

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma

British journal of haematology, 2017-11, Vol.179 (4), p.684-688

2017

Volltextzugriff (PDF)

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

Haematologica (Roma), 2011-04, Vol.96 (4), p.574-582

2011

Volltextzugriff (PDF)

Toll-like receptors: lessons to learn from normal and malignant human B cells

Blood, 2008-09, Vol.112 (6), p.2205-2213

2008

Volltextzugriff (PDF)

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

Journal of hematology and oncology, 2018-12, Vol.11 (1), p.137-137, Article 137

2018

Volltextzugriff (PDF)

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

Frontiers in oncology, 2023-07, Vol.13, p.1196005-1196005

2023

Volltextzugriff (PDF)

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation

British journal of haematology, 2018-01, Vol.180 (1), p.157-159

2018

Volltextzugriff (PDF)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

BMC cancer, 2019-08, Vol.19 (1), p.855-855, Article 855

2019

Volltextzugriff (PDF)

Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization

Cell death & disease, 2019-02, Vol.10 (2), p.101-101, Article 101

2019

Volltextzugriff (PDF)

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

British journal of haematology, 2012-03, Vol.156 (5), p.679-683

2012

Volltextzugriff (PDF)

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells

Frontiers in oncology, 2019-03, Vol.9, p.128-128

2019

Volltextzugriff (PDF)

Cereblon expression in multiple myeloma: not ready for prime time

British journal of haematology, 2013-10, Vol.163 (2), p.282-284

2013

Volltextzugriff (PDF)

Interleukin-6 is a growth factor for nonmalignant human plasmablasts

Blood, 2001-03, Vol.97 (6), p.1817-1822

2001

Volltextzugriff (PDF)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

International journal of molecular sciences, 2017-12, Vol.19 (1), p.40

2017

Volltextzugriff (PDF)

The Origin of the Plasma Cell Heterogeneity

2015

Volltextzugriff (PDF)

A simple flow cytometry‐based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines

Cytometry. Part A, 2015-04, Vol.87 (4), p.285-288

2015

Volltextzugriff (PDF)

Phosphorothioate-Modified TLR9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis

The Journal of immunology (1950), 2009-10, Vol.183 (7), p.4371-4377

2009

Volltextzugriff (PDF)

A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy

Immunological reviews, 2003-08, Vol.194 (1), p.105-111

2003

Volltextzugriff (PDF)

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell

Blood reviews, 2017-07, Vol.31 (4), p.251-259

2017

Volltextzugriff (PDF)

The cancer germ‐line genes MAGE‐1, MAGE‐3 and PRAME are commonly expressed by human myeloma cells

European journal of immunology, 2000-03, Vol.30 (3), p.803-809

2000

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(128)

Publikationsform

Artikel
(134)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(61)
Life Sciences & Biomedicine
(59)
Science & Technology
(59)
Life Sciences
(37)
Hematology
(33)
Cancer
(29)
Cell Line, Tumor
(28)
Oncology
(24)
Biological And Medical Sciences
(20)
Medical Sciences
(19)
Multiple Myeloma
(19)
Multiple Myeloma - Metabolism
(19)
Multiple Myeloma - Pathology
(19)
Apoptosis
(17)
Female
(17)
Multiple Myeloma - Genetics
(13)
Immunodeficiencies. Immunoglobulinopathies
(12)
Immunoglobulinopathies
(12)
Immunopathology
(12)
Multiple Myeloma - Drug Therapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition

Osteoclasts support the survival of human plasma cells in vitro

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

Toll-like receptors: lessons to learn from normal and malignant human B cells

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells

Cereblon expression in multiple myeloma: not ready for prime time

Interleukin-6 is a growth factor for nonmalignant human plasmablasts

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

The Origin of the Plasma Cell Heterogeneity

A simple flow cytometry‐based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines

Phosphorothioate-Modified TLR9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis

A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell

The cancer germ‐line genes MAGE‐1, MAGE‐3 and PRAME are commonly expressed by human myeloma cells

Suchergebnisse filtern